Amylyx Pharmaceuticals AMLX
NASDAQ AMLX
$29.19 -0.09 (-0.31%)
As of: Sep 30, 2026 · 9:47 AM EDT

Amylyx Pharmaceuticals (AMLX) EV to CFO (2023 - 2024)

Updated

Amylyx Pharmaceuticals' EV to CFO came in at -10.92 for Q1 2024.

Analysis

Amylyx Pharmaceuticals (AMLX) EV to CFO (2023 - 2024) Analysis & Trends

Over the trailing twelve months to Mar 31, 2024, Amylyx Pharmaceuticals reported EV to CFO of -76.59; for FY2023, it was 52.46.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Amylyx Pharmaceuticals 3.32 Bn 3.32 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -10.92
Dec 31, 2023 52.46
API Access

Amylyx Pharmaceuticals EV to CFO API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ev-to-cfo&ticker=AMLX&period=max&api_key=YOUR_API_KEY